Status:
COMPLETED
Niclosamide Role in Diabetic Nephropathy
Lead Sponsor:
Tanta University
Conditions:
Diabetic Nephropathies
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This study is randomized, controlled, parallel, prospective clinical study will be conducted on 60 patients diagnosed with type 2 diabetes mellitus at least five years ago. Patients will be recruited ...
Eligibility Criteria
Inclusion
- Patients with Type 2 diabetes mellitus at least 5 years ago
- Stage 2 and 3 diabetic nephropathy (persistent micro- or macroalbuminuria with urinary albumin creatinine ratio (UACR) \>30mg/g) despite treatment with maximum tolerated dose of ACE inhibitors for at least 8 weeks prior to the screening
- Hemoglobin A1c \> 6.5 % with regular use of insulin and/or oral glucose lowering agents
Exclusion
- Type 1 diabetes mellitus
- Severe renal impairment (eGFR\< 30 mL/min/1.73 m2 at screening)
- Pregnant or lactating women
- Chronic heart failure
- Inflammatory or autoimmune disease
- History of kidney disease other than diabetic nephropathy
Key Trial Info
Start Date :
February 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04317430
Start Date
February 1 2020
End Date
April 1 2022
Last Update
October 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Pharmacy, Tanta University
Tanta, Egypt